Ata Dtc Risk Stratification

ATA DTC Initial Risk Stratification Tool

Source: 2015 ATA Management Guidelines — ATA Modified 2009 Initial Risk Stratification System (Table 11).
Haugen et al. Thyroid 2016;26(1). DOI: 10.1089/thy.2015.0020

PURPOSE

The ATA risk tier (Low / Intermediate / High) is assigned at the time of initial surgical pathology and governs:

1. Whether RAI remnant ablation is indicated
2. Intensity of initial TSH suppression
3. Frequency and modality of follow-up
4. When and how to reclassify risk dynamically (see Dynamic Risk Stratification skill)

STEP 1 — Collect Pathologic and Clinical Data

Before assigning tier, confirm:

• Histologic subtype (classic PTC, follicular variant PTC, FTC, Hürthle cell, tall cell, columnar, hobnail, etc.)
• Tumor size (largest focus in cm)
• Unifocal vs. multifocal
• Completeness of resection (R0, R1, R2)
• Extrathyroidal extension: none / microscopic (pT3a ETE) / gross (pT4)
• Lymph node status: clinical N0 / pN0 / pN1 (number, size of largest node, extranodal extension)
• Vascular invasion: none / minimal (≤3 foci) / extensive (≥4 foci)
• Distant metastases: none / suspected / confirmed
• BRAF mutation status (for PTMC with multifocality and ETE)
• Post-surgical serum Tg (while hypothyroid or after rhTSH)

STEP 2 — Assign ATA Risk Tier

✅ ATA LOW Risk

All of the following must apply:

• Complete resection of macroscopic disease
• No local invasion (no microscopic or gross ETE)
• No regional or distant metastases
• No aggressive histologic subtype (tall cell, hobnail, columnar, diffuse sclerosing, solid/trabecular)
• No vascular invasion

AND meets one of these histologic profiles:

Estimated recurrence risk: ~1–2% for intrathyroidal PTC; <5% overall

⚠️ ATA INTERMEDIATE Risk

Any one of the following:

Estimated recurrence risk: ~3–8% (lower end) to 8–25% depending on features

🔴 ATA HIGH Risk

Any one of the following:

Estimated recurrence risk: >50%

STEP 3 — Map Risk Tier to Initial Management Decisions

STEP 4 — Document for Dynamic Risk Reclassification

Record the initial ATA tier as a baseline. After 6–24 months:

• Reclassify using response-to-therapy categories (Excellent / Biochemical Incomplete / Structural Incomplete / Indeterminate)
• The initial tier informs prior probability; the response category drives ongoing management
• → Use the ATA Dynamic Risk Stratification skill for reclassification

CLINICAL GUARDRAILS

• ATA risk tier is a snapshot at surgery — it will be updated as Tg trends and imaging emerge (dynamic risk)
• Microscopic vs. gross ETE matters enormously — microscopic ETE (into perithyroidal fat) = Intermediate; gross ETE (into strap muscle or beyond) = High
• N1 staging is nuanced — the number AND size of nodes drives tier (≤5 micrometastases <0.2 cm = Low; >5 nodes all <3 cm = Intermediate; any node ≥3 cm = High)
• FTC with minimal vascular invasion (1–3 foci) is Low risk; extensive vascular invasion (≥4 foci) is High risk — count the foci
• PTMC multifocality alone is Low — needs BOTH ETE and BRAF mutation to step up to Intermediate
• Tg level at time of surgery should be documented — high postoperative Tg may indicate residual/distant disease and upgrade effective risk even if pathology criteria are intermediate
• This system applies to DTC (PTC + FTC) — medullary and anaplastic thyroid cancers are managed under entirely different frameworks